Transgenic Conversion of Omega‐6 to Omega‐3 Fatty Acids via fat‐1 Reduces Obesity‐Related Intervertebral Disc Degeneration Authors: Shirley N Tang, Kristin L Lenz, Emma Shen, Collin Murray, Nikitha Ada, Sarada Prasad, Mohammed Kuziez, Farshid Guilak, Arin K Oestreich Published: 2026 ABSTRACT ABSTRACTIntroductionLow back pain is a leading cause of disability, largely due to intervertebral disc (IVD) degeneration. Obesity is a risk factor for IVD degeneration and promotes the release of pro‐inflammatory cytokines from adipocytes, leading to inflammation and triggering catabolic degenerative pathways. Western diets high in omega‐6 fatty acids (n‐6 FAs) exacerbate inflammation and obesity, increasing the risk for musculoskeletal diseases. Conversely, omega‐3 (n‐3) FA enriched diets may mitigate these adverse effects. The nonmammalian fat‐1 gene converts n‐6 to n‐3 FAs, thereby reducing n‐6:n‐3 ratios and systemic inflammation. This study aims to elucidate the role of n‐6:n‐3 FA ratios in IVD degeneration by comparing wildtype (WT) and fat‐1 transgenic mice fed n‐6 enriched HFD (n‐6 HFD).MethodsMale and female WT and fat‐1 transgenic mice were fed control or n‐6‐HFD. Body composition (weight, adiposity) and disc height index (DHI) were assessed at 16 weeks of age using microCT imaging. Chronic effects were evaluated at 60 weeks of age via serum cytokines (inflammatory panel), bone parameters (microCT), DHI, and histological grading of H&E staining.ResultsAt 16 weeks, HFD increased adiposity, while fat‐1 mice exhibited reduced weight gain. In vivo microCT revealed lower DHI in HFD‐fed animals but higher DHI in fat‐1 groups, with sex and lumbar level differences. At 60 weeks, inflammatory cytokines (IL‐6, IL‐17A) were elevated in the serum of WT HFD mice compared to fat‐1 HFD mice. Histopathological staining revealed increased fibrosis, cell loss, and matrix disorganization in the IVDs of HFD‐fed WT mice. However, IVDs of fat‐1 mice were protected from the degenerative effects of HFD.ConclusionsLowering the n‐6:n‐3 FA ratio via endogenous fat‐1 activity modulates systemic inflammatory profiles in a sex‐dependent manner and protects against obesity‐driven IVD degeneration. These findings highlight the potential of dietary interventions or fat‐1 gene therapy for treating obesity‐associated IVD pathology.Keywords: diet, inflammation, metabolism, polyunsaturated fatty acids (PUFAs), spine Introduction Low back pain (LBP) is a leading cause of disability worldwide, impacting approximately 619 million people globally, and its prevalence continues to escalate [1, 2]. While the etiology of LBP is complex and multifactorial, epidemiological evidence estimates that approximately 40% of cases are attributed to degeneration of the intervertebral disc (IVD) [3, 4, 5]. IVDs are fibrocartilaginous structures sandwiched between vertebral bodies and are largely avascular and aneural, functioning to allow spinal mobility. In the healthy state, the IVD is characterized by a hydrated gelatinous nucleus pulposus (NP) core surrounded by collagen rings, which form the annulus fibrosus (AF) and are cranially and caudally bordered by the cartilage endplates (CEPs). With degenerative disc disease, the IVD is characterized by decreased disc height, altered mechanical properties, loss of critical extracellular matrix (ECM) integrity, inflammation, and neurovascular invasion, ultimately leading to downstream pain [6, 7]. While therapies such as pain medication, physical therapy, and surgery are used clinically to treat symptoms of LBP, none of these methods target the underlying disease pathology, which often leads to recurrent pain, further warranting the need for preventative measures for IVD degeneration. The progression of IVD degeneration is driven by risk factors such as age, genetics, mechanical stress, smoking, and obesity. Obesity is a complex systemic disease characterized by excessive body fat and is a growing epidemic across all ages [8]. While mechanical stress due to weight gain is a contributing factor to IVD degeneration, biochemical mechanisms appear to play a more important role in the degeneration of cartilaginous tissues [9]. Expansion of white adipose tissue (WAT) leads to systemic chronic inflammation, release of adipokines, infiltration of immune cells and pro‐inflammatory cytokines, ultimately leading to an imbalance in IVD homeostasis and triggering degenerative catabolic pathways [10, 11, 12]. In addition to obesity, diabetes further drives IVD degeneration through chronic hyperglycemia, accumulation of advanced glycation end products (AGEs), ultimately leading to inflammatory signaling and catabolic matrix degradation [13, 14, 15, 16, 17]. Unfortunately, this consistent progression of LBP and obesity leads to a vicious cycle of pain, reduced mobility/physical activity, poor dietary habits, and further weight gain [10, 11]. Western diets high in omega‐6 fatty acids (n‐6 FAs), such as those found in seed oils and fried foods, exacerbate inflammation, metabolic disease, and obesity, which increase the risk for cardiovascular and musculoskeletal diseases [18]. Conversely, consuming omega‐3 fatty acid (n‐3 FA) rich diets, such as fish and nuts, reduces inflammation, ameliorates metabolic syndrome, and alters circulating adipokine levels, which may be protective in the context of IVD injury. The fat‐1 gene is a nonmammalian gene originating in Caenorhabditis elegans and encodes the n‐3 FA desaturase capable of endogenously converting n‐6 FAs to n‐3 FAs [19]. Previous studies using transgenic fat‐1 mice have validated the reduction of systemic n‐6:n‐3 ratios in obese mice and shown reduced pro‐inflammatory cytokines, increased anti‐inflammatory cytokines, and a reduction in post‐traumatic osteoarthritis (PTOA) severity [19, 20]. In addition, adenovirus‐mediated delivery of fat‐1 offers protection against metabolic dysfunction, cellular senescence, and osteoarthritis (OA) [21] in mouse models, further supporting the therapeutic potential of fat‐1 in alleviating obesity and related diseases. However, the relationship between n‐6:n‐3 FA and IVD degeneration has not been studied. This study aims to elucidate the effect of high n‐6 diet‐induced obesity on the IVD and evaluate the effect of fat‐1 as a protective mechanism for IVD degeneration. Thus, we hypothesized that (1) n‐6 enriched HFD increases IVD degeneration and (2) fat‐1 conversion of n‐6 to n‐3 may be preventative against obesity‐related IVD degeneration. To do so, we put wildtype (WT) and fat‐1 transgenic mice on either control or n‐6 enriched HFD with assessments at 16 and 60 weeks for overall body composition, systemic inflammation, bone parameters, disc height, and histomorphometry for IVD degeneration score. Materials and Methods Animal Studies All experimental procedures described in this study were approved by the Washington University Department of Comparative Medicine (DCM) Institutional Animal Care and Use Committee. Hemizygous fat‐1 transgenic (Cat# 020097) male mice on a C57BL/6 background were purchased from Jackson Laboratories and mated to WT C57BL/6 females (Cat# 000664) to generate mice for this study. Mice were placed on either a control diet (13% fat (6% kcal PUFA), n‐6:n‐3 FA ratio = 10:1) (Research Diets Inc., Cat# D19052001) or n‐6 enriched HFD (60% fat (24% kcal PUFA), n‐6:n‐3 FA ratio = 25:1) (Research Diets Inc., Cat# D11120105) starting at 4 weeks of age. Mice were group housed (5 mice max per cage) with free access to food and water on a 12/12 h light/dark cycle. Weekly body weights were collected until the mice reached 16 weeks of age, along with monthly body weights through 60 weeks of age. At 16 weeks of age, a group of mice underwent microcomputed tomography (microCT) imaging for body composition (body fat, disc height index [DHI], and vertebral bone mineral density [BMD]) and metabolic testing (glucose tolerance test [GTT] and insulin tolerance test [ITT]). At 60 weeks of age, a group of mice were imaged via dual‐energy x‐ray absorptiometry (DEXA) for body composition, metabolic testing (GTT and ITT) and euthanized via exsanguination to collect blood, followed by cervical dislocation. Lumbar spines (T13‐S1) were collected and fixed in 10% neutral buffered formalin (NBF) for downstream microCT and histology, as shown in Figure 1. The number of animals used for each assessment, time, diet, and genotype are individually stated in each figure legend. Study design: male and female wildtype (WT) and transgenic fat‐1 mice were placed on omega‐6 (n‐6) enriched high‐fat diets (HFD) or respective control diets at 4 weeks of age. 16‐week and 60‐week‐old timepoints were assessed for body fat, metabolism (glucose tolerance test [GTT] and insulin tolerance test [ITT]), inflammation, intervertebral disc degeneration, and bone microstructure. Figure created in BioRender. In Vivo Assessments microCT and (DEXA) Body Fat Assessments At 16 weeks old, mice were anesthetized under 3% isoflurane and microCT imaged on the Bruker SkyScan 1176 as previously described on the following settings: Filter = 1 mm Al, resolution = standard, pixel size = 35 μm, voltage = 50 kV, 354 μA [22]. Scans were reconstructed using NRecon to include the L1–L5 abdominal region and analyzed on CTAn for adipose tissue volume and total tissue volume. Body fat was calculated as a percentage of adipose tissue volume over total tissue volume. At 60 weeks of age, mice were anesthetized under 3% isoflurane and imaged via DEXA scanning using the Lumar PIXImus (General Electric, Fitchburg, WI) to quantify body fat and body BMD. Disc Height Assessments For DHI at 16 weeks, microCT scans were reconstructed in NRecon to include only the lumbar spine before 3D alignment using DataViewer. Sagittal volumes of interest (VOIs) were saved and opened in CTAn. The medial sagittal image slice was determined by locating the middle between left and right lateral sides of the spine, followed by measurement of the posterior, middle, and anterior disc height and adjacent disc heights cranially and caudally. DHI was calculated as described in Tajerian et al. for L1–L5 IVDs [23]. For vertebral BMD, transverse VOIs were saved and regions of interest drawn in CTAn to include only the vertebral bodies, which were then analyzed using batch manager for whole vertebral bodies of L1–L5 vertebrae. GTT and ITT For GTT, mice were fasted for 6 h with baseline glucose measurement via tail vein bleed (Glucocard Vital). Mice were given 1 mg/kg dextrose (10% dextrose in sterile 1XPBS: 1% volume/g body mass) intraperitoneally. Glucose was measured at 15, 30, 60, and 120 min postinjection. For ITT, mice were fasted for 4 h with baseline glucose measurement followed by intraperitoneal injection of insulin at 0.75 U/kg body mass (Humalin R, 0.075 U/m: 1% volume/g body mass). Glucose measurements were recorded over a 2‐h period at the same timepoints as GTT. GTT and ITT curves were plotted as glucose over time, with the area under the curve (AUC) quantified as a measure of impaired glucose tolerance and insulin sensitivity. Ex Vivo Assessments Serum Inflammatory Profile Mice were fasted overnight and anesthetized under 3% isoflurane and blood was collected via retro‐orbital bleed. Mice were euthanized immediately after blood collection. Blood was collected in microtainer blood collection tubes and centrifuged at 10 000g at 4°C for 10 min to separate serum. Serum was isolated and stored at −80°C. To assess systemic inflammation, serum samples were shipped on dry ice to Eve Technologies (Calgary, AB, Canada) for the Mouse High Sensitivity 18‐Plex Discovery Assay. GM‐CSF, IFNγ, IL‐1α, IL‐1β, IL‐2, IL‐4, IL‐5, IL‐6, IL‐7, IL‐10, IL‐12(p70), IL‐13, IL‐17A, KC/CXCL1, LIX, MCP‐1, MIP‐2, and TNFα protein levels were assessed using this multiplexing analysis and performed using the Luminex 200 system. MicroCT Lumbar spines with surrounding muscles intact (T13‐S1) were fixed in 10% NBF for 48 h before transferring to 70% ethanol. Spines were imaged on the Bruker Skyscan 1176 at the following settings: Filter = 1 mm Al, resolution = high, image pixel size = 8.75 μm, voltage = 45 kV, 500 μA with respective phantoms (0.25 and 0.75 g/cm3 hydroxyapatite) and underwent the same pipeline as described in the in vivo microCT for DHI and bone parameters. Due to the higher resolution of ex vivo microCT at 60 weeks, trabecular and cortical properties were also analyzed via CTAn with exclusion of the CEP to correctly threshold cortical versus trabecular bone. Histology and Degeneration Scoring Post‐microCT imaging, fixed spines were decalcified in Immunocal Decalcifier (StatLab, #1414) for 72 h, processed in a tissue processor, sectioned into vertebrae‐IVD‐vertebrae segments, paraffin embedded, and cut into 8 μm coronal sections throughout the thickness of the IVD. Medial sections were stained with hematoxylin and eosin (H&E) for IVD scoring and Safranin O/Fast Green for cartilage analysis. H&E slides were graded using the 14‐feature scoring system for IVD degeneration as described by Melgoza et al. [24]. L4 and L5 lumbar level IVDs were used for scoring assessment due to their clinical relevance to human lower lumbar level degeneration and significant changes in DHI. The images were scored by three independent, blinded scorers, with data averaged across scorers as a single score for each animal and vertebral level. Statistical Analysis All data were graphed and analyzed using GraphPad Prism version 10.6.1. The Shapiro–Wilk test was used to verify data normality, followed by a two‐way ANOVA with multiple comparisons by Tukey post hoc test to compare between all groups at an α of 0.05 for body weight, body fat, GTT, ITT, DHI, inflammatory cytokine expression, IVD degeneration score, and bone parameters, respectively. Growth curves were analyzed with a three‐way ANOVA to account for genotype, diet, and time with Tukey post hoc. Female and male data were analyzed separately and not directly compared, as there exist inherent confounding variables between the sexes. Statistical outliers were removed from data analysis using GraphPad Prism ROUT function with Q = 1% and reported with each figure legend if outliers were removed. Significant ANOVA effects of genotype, diet, or interaction are reported within each figure. Figures are presented as mean ±95% confidence intervals (CIs) with individual data points indicating individual mice. Sample sizes for each group are indicated in each figure legend. Results 16 Week Results Body Mass and Adiposity To assess body composition, mice were weighed weekly up to 16 weeks of age, and fat content was measured using in vivo microCT. HFD feeding increased body weight in both female and male mice (Figure 2A,B). WT mice fed a HFD showed an initial rapid weight gain starting at 11 weeks of age (7 weeks of HFD) in females and 10 weeks of age (6 weeks of HFD) compared to WT control‐fed mice (Figure 2A,B). Meanwhile, HFD‐fed fat‐1 mice were more resistant to weight gain early on and didn't weigh more than control‐fed counterparts until 13 weeks of age (9 weeks of HFD) in females and 14 weeks of age (10 weeks of HFD) in males (Figure 2A,B). While not significant, fat‐1 female mice had 10% lower body mass compared to their respective HFD‐fed WT controls (p = 0.062) at 16 weeks of age (Figure 2A). Both WT and fat‐1 male mice showed similar weights at 16 weeks of age (12 weeks of HFD) (Figure 2A). HFD increased body size and adiposity as shown by representative abdominal microCT cross‐sections and quantitative analysis in both female and male mice (Figure 2C,D). Interestingly, the fat‐1 genotype did not change adiposity in female mice but decreased adiposity in HFD‐fed male mice compared to HFD‐fed WT (Figure 2D). 16 week body composition: (A) weekly growth curves of female mice up to 16 weeks with respective 16 week body weight bar graphs. Sample size: WT control = 23, fat‐1 control = 22, WT HFD = 24, fat‐1 HFD = 26. Arrows indicates start of significant (p < 0.05) body weight difference between control and HFD‐fed groups of WT mice (black) and fat‐1 mice (red). (B) Weekly growth curves of male mice up to 16 weeks with respective 16‐week body weight bar graphs. Sample size: WT control = 9, fat‐1 control = 9, WT HFD = 10, fat ‐1 HFD =8. Arrows indicates start of significant (p < 0.05) body weight difference between control and HFD‐fed groups of WT mice (black) and fat‐1 mice (blue). Complete ANOVA terms for growth curves can be found in Table S1. (C) Representative in vivo microCT cross‐sections of the male mice abdomen, with white depicting adipose tissue and dark areas depicting muscle. (D) 16‐week body fat of female and male mice characterized by %adipose tissue (adipose tissue volume/total volume) from microCT scans. Female sample size: WT control = 13 (1 outlier removed), fat‐1 control = 13, WT HFD = 15, fat ‐1 HFD =15 (1 outlier removed). Male sample size: WT control = 10, fat‐1 control = 9, WT HFD = 15, fat‐1 HFD = 9. Data presented as mean ±95% CI. Main effects of diet and fat‐1 genotype were determined using two‐way ANOVA and are indicated in the upper left corner. Effects of interaction were not statistically significant unless explicitly indicated in the panel. *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001. Compact letter display: Different letters indicate statistical significance. Data points represent individual mice. Metabolism To assess metabolic dysfunction at 16 weeks, GTT and ITT were used as measures of glucose tolerance and insulin resistance. In GTT, female and male HFD‐fed WT mice exhibited increased AUC, indicating impaired glucose tolerance, while fat‐1 mice showed a protective effect against HFD (Figure 3A,B). Similarly, HFD feeding impaired insulin sensitivity (higher AUC) in both sexes (main effect of diet) (Figure 3C,D). However, the fat‐1 transgene only protected insulin sensitivity in male mice (Figure 3C,D). 16 week metabolic assessment: (A, B) 16 week glucose tolerance test (GTT) with (left) glucose curve and (right) calculated area under the curve (AUC) for female and male mice, respectively. Higher AUC indicates impaired glucose tolerance. Female sample size: WT control = 14, fat‐1 control = 13, WT HFD = 14, fat ‐1 HFD = 16. Male sample size: WT control = 10, fat‐1 control = 9, WT HFD = 15, fat‐1 HFD = 9. (C, D) 16 week insulin tolerance test (ITT) with (left) glucose curve and (right) AUC. Higher AUC indicated increasing insulin resistance. Female sample size: WT control = 7, fat‐1 control = 9, WT HFD = 12, fat ‐1 HFD =10. Male sample size: WT control = 9, fat‐1 control = 15, WT HFD = 9, fat‐1 HFD = 9. Data presented as mean ±95% CI. Effects of Diet and fat‐1 are indicated in the upper left corner. Effects of interaction were not statistically significant unless explicitly indicated in the panel. **p < 0.01, ***p < 0.001, ****p < 0.0001. Compact letter display: different letters indicate statistical significance. 60 week GTT and ITT can be found in Figure S2. DHI and Vertebral Bone Properties As a characteristic of IVD degeneration, in vivo DHI was measured in microCT scans for all lumbar IVDs using the medial sagittal cross‐section (Figure 4A). No significant differences between HFD or fat‐1 genotype were observed in L1, L2, or L3 IVDs (Figure S1). However, HFD significantly decreased disc height in both WT and fat‐1 female mice at L4, while no differences were observed in L5 (Figure 4B). Interestingly, female control diet‐fed fat‐1 mice showed smaller L4 DHI compared to control‐fed WT mice (Figure 4B), indicating fat‐1 female mice may innately have smaller L4 discs compared to WT mice. In contrast, HFD significantly decreased DHI in WT male mice at L5, but male fat‐1 mice were resistant to disc height decrease (Figure 4B). Whole vertebrae BMD was also assessed in L4 and L5 vertebrae. HFD decreased BMD in female mice at both the L4 and L5 vertebrae (main effect of HFD). However, fat‐1 genotype did not impact BMD in female mice. In contrast, HFD decreased BMD in WT male mice, but not fat‐1 male mice, indicating fat‐1 male mice were partially protected from the detrimental effects of HFD on vertebral BMD (Figure 4C). 16 week disc height index and bone mineral density: (A) middle sagittal cross‐section of the mouse lumbar spine (L1–L6) with yellow lines indicating anterior, middle, and posterior vertebrae heights and red lines indicating anterior, middle, and posterior disc heights used in the calculation of disc height index (DHI). (B) 16 week in vivo DHI of L4 and L5 IVDs in female and male mice, respectively. (C) Vertebral bone mineral density (BMD) of L4 and L5 vertebrae in female and male mice. Data presented as mean ±95% CI. Main effects of diet and fat‐1 genotype were determined using two‐way ANOVA and are indicated in the upper left corner. Effects of interaction were not statistically significant unless explicitly indicated in the panel. *p < 0.05, **p < 0.01, ***p < 0.001. NS indicates no significant effects of diet, genotype, or interaction. Compact letter display: different letters indicate statistical significance. Data points represent individual mice. Female sample size: WT control = 13, fat‐1 control = 12, WT HFD = 14, fat ‐1 HFD = 15. Male sample size: WT control = 10, fat‐1 control = 9, WT HFD = 12, fat‐1 HFD = 9. DHI for levels L1‐L3 can be found in Figure S1. 60 Week Results Body Mass, Adiposity, Whole‐Body BMD, and Metabolism To assess the effects of chronic HFD and fat‐1 genotype, mice were weighed monthly with DEXA imaging at 60 weeks for body fat and whole‐body BMD. HFD increased body mass in both female and male mice (Figure 5A,B). While trends of lower body mass were observed in both male (15.7% decrease, p = 0.1) and female (15.9% decrease, p = 0.22) HFD‐fed fat‐1 mice compared to diet‐matched WT controls, they were not statistically significant (Figure 5A,B). Similarly, HFD‐fed WT female mice had a 26.9% increase in adipose tissue compared to control‐fed WT mice, but had similar adiposity to HFD‐fed fat‐1 mice (Figure 5D). HFD increased adipose tissue of male mice at 60 weeks of age (main effect of diet), but no significant differences between groups were observed. Interestingly, despite weight gain and adiposity, no effects on overall body BMD were observed in female mice due to fat‐1 genotype. However, HFD decreased BMD in male mice, which was not mitigated by fat‐1 genotype (Figure 5E). No significant differences were seen in GTT or ITT at 60 weeks due to HFD or fat‐1 genotype (Figure S2). 60 week body composition: (A) monthly growth curves of female mice up to 14 months with respective 60 week body weight bar graphs. Sample size: WT control = 7 (1 outlier removed), fat‐1 control = 7, WT HFD = 16, fat ‐1 HFD =11(1 outlier removed). (B) Monthly growth curves of male mice up to 14 months with respective 60 week body weight bar graphs. Growth curve *indicates a significant different between HFD‐fed WT and fat‐1 (p < 0.05). Sample size: WT control = 9, fat‐1 control = 9, WT HFD = 10, fat ‐1 HFD = 8. (C) Representative in vivo DEXA scans of male mice. (D) 60 week body fat of female and male mice characterized by %adipose tissue (adipose tissue volume/total volume) from DEXA scans. Data presented as mean ±95% CI. Main effects of diet and fat‐1 genotype were determined using two‐way ANOVA and are indicated in the upper left corner. No significant effects of interaction were observed. *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001. Compact letter display: different letters indicate statistical significance. Data points represent individual mice. Systemic Inflammation To assess systemic inflammation, serum was collected at 60 weeks and run on an Eve multiplex panel. Data revealed high variability between mice. No differences in pro‐inflammatory cytokines were observed in female mice (Figure 6A). In contrast, HFD increased interleukin‐6 (IL‐6) and interleukin‐17 (IL‐17A) in WT male mice but not in fat‐1 male mice, indicating fat‐1 genotype offered partial protection from the detrimental effects of HFD (Figure 6B). Anti‐inflammatory cytokines interleukin‐4 (IL‐4) and interleukin‐10 (IL‐10) were increased in control diet‐fed fat‐1 female mice compared to WT but had no significant effect in HFD‐fed mice (Figure 6C). Meanwhile, these same cytokines were extremely low across all male mice, except for interleukin‐13 (IL‐13) which was increased in fat‐1 mice compared to WT on control diet only (Figure 6D). No significant differences were observed in other cytokines measured between HFD‐fed fat‐1 and WT mice (Figures S3 and S4). Serum inflammation: (A, B) 60 week serum inflammatory cytokines in female and male mice (IL‐1α, IL‐1β, IL‐6, IL‐17A). (C, D) 60 week serum anti‐inflammatory cytokines (IL‐4, IL‐10, IL‐13) in female and male mice. Data presented as mean ±95% CI. Main effects of interaction, diet, and fat‐1 genotype are indicated in the upper left corner using a two‐way ANOVA. *p < 0.05, **p < 0.01. No indication indicates no main effects. Compact letter display: different letters indicate statistical significance between groups. Female sample size: WT control = 8, fat‐1 control = 8, WT HFD = 17, fat‐1 HFD = 11. Male sample size: WT control = 9, fat‐1 control = 9, WT HFD = 12, fat‐1 HFD = 9. Additional cytokine data can be found in Figures S3 (female) and S4 (male). Ex Vivo DHI To assess disc height at 60 weeks, spines were excised from mice post euthanasia, with surrounding muscles intact, and imaged via microCT, with the medial sagittal section used for DHI measurements. Similar to spines assessed at 16 weeks, no significant effects of fat‐1 were observed in L1, L2, or L3 levels (Figure S5). Unlike animals at 16 weeks, HFD‐fed female mice showed decreased DHI compared to control‐fed WT in both L4 and L5 levels, while no effects of diet or genotype were seen in male mice (Figure 7). 60 week disc height index: (A) 60 week old ex vivo disc height index (DHI) of L4 IVDs in female and male mice. (B) 60week old ex vivo DHI of L5 IVDs in female and male mice. Data presented as mean ±95% CI. Main effects of diet and fat‐1 genotype or interaction are indicated in the upper left corner using a two‐way ANOVA. No indications indicate no significance of main effect. Female sample size: WT control = 5, fat‐1 control = 5, WT HFD = 10 (1 outlier removed), fat ‐1 HFD = 9 (1 outlier removed). Male sample size: WT control = 7, fat‐1 control = 6, WT HFD = 10, fat‐1 HFD = 7 *p < 0.05, **p < 0.01, and ***p < 0.001. Compact letter display: different letters indicate statistical significance. Data points represent individual mice. DHI for L1–L3 can be found in Figure S5. Ex Vivo Vertebral Bone Properties For vertebral bone microstructure, high‐resolution microCT images of spines were acquired, followed by assessment of whole vertebral bone (trabecular, cortical, and CEP regions) (Table S2), cortical bone (Table S3), and trabecular bone (Table S4) for L4 and L5 levels. There were no gross changes in whole vertebral bone properties due to HFD or fat‐1 genotype in either female or male mice (Table S2). In the cortical bone, HFD did not change female vertebrae but significantly increased tissue area (T.Ar), cortical area (Ct. Ar), and cortical thickness (Cs.Ts) in both the L4 and L5 vertebrae of male mice (Table S3). However, fat‐1 genotype had minimal effects on vertebral cortical bone outcomes in either sex (Table S3). In trabecular bone, HFD minimally influenced trabecular bone properties in L4 and L5 vertebrae of female mice (Table S4), but fat‐1 genotype increased BV/TV in L4 and decreased trabecular pattern factor (Tb.Pf) in L5 vertebrae (Table S4). In male mice, HFD increased trabecular separation (Tb.Sp) and decreased trabecular number in both L4 and L5 vertebrae (Table S4). IVD Degeneration Score To assess the degree of structural IVD degeneration, L4 and L5 vertebrae‐IVD‐vertebrae segments were stained with Safranin O/Fast Green for qualitative cartilage and glycosaminoglycan (GAG) structure and H&E for tissue and cellular morphology, followed by quantitative IVD degeneration scoring. Safranin‐O/Fast Green staining revealed minor signs of IVD degeneration in WT and fat‐1 mice fed control diets, indicating a mild effect of aging at 60 weeks. HFD‐fed WT mice showed minimalization of NP structure and area, ranging from fibrotic NP with decreased cellularity and loss of NP‐AF border, to complete NP loss amongst male and female mice. Fissures and clefts were observed in all AF tissue of mice regardless of diet, but with more severity and disorganization in HFD‐fed mice compared to the control diet (Figure 8A). Meanwhile, fat‐1 mice were protected from HFD‐related IVD structural degeneration and had degeneration scores similar to control diet‐fed mice in both sexes (Figure 8B,C). Intervertebral disc degeneration: (A) representative SafraninO/FastGreen (Top) and hematoxylin/eosin (H&E) (bottom) staining of male mice L4 IVDs for control and n‐6 HFD‐fed WT and fat‐1 transgenic mice, respectively. Yellow scale bar = 500 μm (B) L4 IVD degeneration score for female (top) and male mice (bottom). (C) L5 IVD degeneration score for female (top) and male (bottom) mice. Data presented as mean ±95% CI. Main effects of diet and fat‐1 are indicated in the upper left corner using a two‐way ANOVA. Female sample size: WT control = 7, fat‐1 control = 7, WT HFD = 13, fat ‐1 HFD = 10. Male sample size: WT control = 8, fat‐1 control = 8, WT HFD = 11, fat‐1 HFD = 7.*p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001. Compact letter display: different letters indicate statistical significance (p < 0.05). Discussion Overview Chronic LBP and obesity are both leading contributors to global disability and require mechanistic elucidation to develop preventative measures. In this study, WT and fat‐1 transgenic mice were placed on control diet or n‐6 enriched HFD and assessed for obesity, metabolic dysfunction, systemic inflammation, bone microstructure, and IVD degeneration via DHI and histological degeneration scores. We found that (1) mice fed n‐6 HFD exhibited obesity as evidenced by increased body mass, adiposity, and metabolic dysfunction, while (2) fat‐1 genotype may have a protective role in regulating downstream adiposity and inflammation in a sex‐dependent manner, and (3) fat‐1 protects against morphological disc degeneration but not disc height under chronic HFD stress. fat‐1 Genotype Has a Protective Role in Body Composition Against HFD Feeding HFD feeding is a well‐established mouse model of obesity supported by significantly increased body weight, size, and adiposity in both female and male mice compared to control‐fed mice, as established in this study and our previous studies [20, 21, 22]. In 16‐week‐old HFD‐fed groups, fat‐1 female mice showed lower body weight compared to WT mice, with no differences in % adiposity. Meanwhile, male fat‐1 mice showed no differences in body weight compared to WT mice, yet decreased adiposity. However, under chronic HFD exposure (60 weeks), no protective effects of fat‐1 were observed in terms of body mass, adiposity, or whole‐body BMD. While weight differences between fat‐1 and WT mice were not statistically significant, female HFD‐fed fat‐1 mice had an overall 15.9% body weight decrease, while male HFD‐fed fat‐1 mice had an overall 15.7% body weight decrease compared to sex‐matched HFD‐fed WT mice. Studies have shown that a more than 10% decrease in body weight results in significant clinical disease modifications in terms of improved metabolism, diabetic risk and cardiovascular diseases [25, 26]. Therefore, the overall reduction of body weight in HFD‐fed fat‐1 mice may have partially contributed to the protective effects observed in the IVD. GTT and ITT assessments at 16 weeks of age showed impaired glucose tolerance in all mice fed HFD, while transgenic fat‐1 mice showed protection against glucose intolerance and insulin resistance. These data are consistent with other studies utilizing fat‐1 mice [27, 28]. However, no effects of glucose or insulin tolerance were observed at 60 weeks, potentially as an effect of aging, which also contributes to impairment of glucose and insulin sensitivity [29]. PUFA concentrations were not directly measured in this study; however, our previous studies using the fat‐1 transgenic mouse have established the capability of fat‐1 to reduce n‐6:n‐3 PUFA ratios in systemic serum via mass spectrometry [20, 21]. The fatty acid content of fat‐1 transgenic mice has also been largely characterized in literature [19, 20, 27, 30, 31, 32, 33, 34, 35, 36, 37]. Together, these data suggest that fat‐1 may have an initial protective role against HFD‐induced obesity via reduction of the n‐6:n‐3 ratio; however, the effects are less prevalent under long‐term HFD feeding. Sexual Dimorphism in the Protective Role of fat‐1 and Inflammatory Pathways While obesity‐related joint diseases were once thought of mainly as a result of mechanical imbalance, the role of obesity as a more complex systemic disease has surfaced over the past years in the dysregulation of expanded adipose tissue depots, systemic circulating cytokines, adipokines, and overall systemic inflammation [9, 11, 38]. In this study, a HFD increased the pro‐inflammatory cytokines IL‐6 and IL‐17A, specifically in WT male mice, and tended to increase IL‐1β (main effect of diet p = 0.06) which is consistent with previous studies [21]. However, HFD did not increase inflammatory cytokines in female mice. This data supports previous findings of increased inflammation in male mice vs. female mice in DIO models of obesity [39]. Specifically, this n‐6‐rich HFD has been shown to increase systemic IL‐1α, IL‐1β, and IL‐6, while fat‐1 gene therapy ameliorated these effects [21]. Previous work has shown that these cytokines are key pro‐inflammatory cytokines driving IVD degeneration, contributing to matrix breakdown, matrix synthesis inhibition, and pain [40, 41, 42]. However, further work is necessary to determine if changes in systemic proinflammatory cytokines impacted local immune cell infiltration and matrix breakdown in the degenerating disc. The effects of the fat‐1 genotype also exhibited sexual dimorphic effects on inflammatory cytokines. Systemic inflammatory cytokines, including IL‐1α, IL‐6, and IL‐17A, were lower in HFD‐fed fat‐1 male mice. In contrast, anti‐inflammatory cytokines IL‐4, IL‐10, and IL‐13 were highly upregulated in fat‐1 female mice with very low expression in male mice overall. This suggests a sexually dimorphic mechanism in how specific inflammatory cytokines play a role in obesity. These sex differences may be a complex balance of hormones (higher estrogen in females), which in turn influence macrophage polarity toward higher proportions of M1‐like cells in male mice, leading toward pro‐inflammatory pathways and higher proportions of M2‐like cells in female adipose, leading toward more anti‐inflammatory pathways [43]. Thus, while shifting the n‐6:n‐3 FA ratio in the fat‐1 mouse may partially reduce systemic inflammatory cytokines in a sex‐specific manner, further studies directly correlating changes in n‐6:n‐3 ratios and local inflammation within the IVD itself would provide additional insights into the mechanisms of our findings. fat‐1 Genotype Is Protective Against HFD‐Induced IVD Degeneration DHI is a standard radiographic measurement of the IVD space and commonly used as a proxy for IVD degeneration [44]. After 16 weeks of HFD exposure, DHI decreased in L4 IVDs of male and female WT mice and L5 IVDs of male but not female mice. Meanwhile, no significant differences of diet were observed in higher L1, L2, or L3 levels, suggesting an interesting clinically relevant degeneration as human IVD occurs mainly in the L4–L5 levels [45]. In mice, this may be due to the location of surrounding abdominal visceral and subcutaneous fat. At 60 weeks, all IVDs harvested for histopathology showed signs of age‐induced mild degeneration even in control diet‐fed mice, evidenced by cell loss and moderate fibrosis in the NP region along with minor clefts/fissures in the AF, with no major differences in the CEP. These findings are consistent with other reports of age‐related IVD degeneration classified by “mild” degeneration criteria [24, 46]. In contrast, n‐6 HFD‐fed WT mice showed variable, yet strong changes in IVD morphology ranging from loss of NP cellularity to complete NP loss, AF protrusion, AF fissures, loss of NP‐AF boundary, and clefts in the CEP. Importantly, this is reflected in both male and female IVD degeneration scores in the range of moderate to severe IVD degeneration. Interestingly, male mice showed a protective effect of fat‐1 genotype in maintaining vertebral BMD at the L4 and L5 levels, suggesting an interplay between bone and IVD crosstalk that warrants further exploration. However, these protective effects on IVD morphology and BMD were not observed on disc height at 60 weeks, with male DHI leveling out across diet and genotype in L4 and L5 IVDs of male mice and decreased disc height in L4 and L5 of female mice. A critical limitation to note is that mice were euthanized via CO2 followed by cervical dislocation, which may have introduced variability in DHI due to pulling of the axial skeletal; however, this procedure was performed on all the animals in this study uniformly. Therefore, it is possible that DHI outcomes were affected by the procedure, and future studies ensuring no physical pull on the spine are needed to definitively show DHI effects. The IVD of HFD‐fed fat‐1 mice also showed similar histological pathology compared to the control diet, indicating a protective/preventative role of fat‐1 in obesity‐induced IVD degeneration. Napier et al. also observed the protective role of increasing n‐3 levels on the IVD using a rat IVD puncture model with n‐3 dietary supplementation which showed protection of NP hydration 2 months post injury compared to non‐supplemented control animals. These findings are consistent with previous studies supporting the role of dietary fatty acids and their significant association with OA severity where n‐3 enriched HFD enhanced ear wound repair and mitigated PTOA severity [47]. These studies, taken together with the present study, further highlight the importance of the n‐6:n‐3 FA ratio in IVD disease progression. Furthermore, while fat‐1 mice showed histopathological protection at 60 weeks, DHI was not uniformly protected—indicating that, while fat‐1 is protective structurally, future studies involving analysis of other IVD degeneration parameters are warranted such as functional mechanical measures and disc hydration to fully characterize different aspects of IVD degeneration. Diet‐induced obesity models are necessary to fully recapitulate the obese milieu characterized by increased adiposity, systemic inflammation, and metabolic disease. In the current study, mice had increased adiposity, systemic inflammation, and impaired glucose tolerance with insulin resistance. The multifactorial nature of obesity makes it difficult to discern which aspect of the obese milieu drives degenerative IVD pathology. Rodent models of Type 1 and 2 diabetes indicate that diabetes, but not obesity alone, significantly increases IVD degeneration through the AGE/inflammation axis [13, 15, 16]. Similar to the results of our n‐6 HFD fed mice, diabetic mice exhibit IVD height loss, decreased vertebral BMD, increased inflammation, and increased IVD pathology and degeneration score [13, 14, 17]. Therefore, it is possible that metabolic dysfunction in our diet‐induced obesity model contributed to the observed IVD degeneration. In this study, the fat‐1 genotype offered some protection from diet‐induced glucose and insulin intolerance in male and more modestly in female mice, which may warrant future studies to evaluate the effects of fat‐1 on IVD degeneration in diabetic mouse models. Potential of fat‐1 as a Therapeutic Target in Joint Disease In previous studies from our group, we have shown the protective role of fat‐1 in reducing PTOA severity using transgenic fat‐1 mice in a sex dependent manner [20]. Recently, we have also shown the therapeutic effect of AAV8‐fat‐1 gene therapy for PTOA and obesity which resulted in reduction of cellular senescence, premature obesity induced aging, mitigation of metabolic dysfunction, and joint degeneration with no evidence of negative systemic impact [21]. In addition to anti‐inflammatory, metabolic, and senolytic effects, fat‐1 has also shown neuroprotection in spinal cord injury, suppression of dermatitis, protection from liver injury, and cancers [30, 31, 32, 33, 34, 48, 49], highlighting its strong potential as a broad systemic therapy targeted for obesity and downstream systemic diseases. Study Limitations and Future Outlook There were several limitations to this study which should be considered in the interpretation of our findings. In this study, data collected at the 16‐ and 60‐week timepoints were not collected from the exact same cohort of animals, preventing longitudinal assessments. Closer observation of monthly body mass suggests weight loss in male mice at 11 months (Figure 4B), which may be due to teeth overgrowth on soft HFD, a potential contributor to mouse‐to‐mouse variability in this data. Following metabolic and IVD degeneration over time in the same set of animals may have provided more resolution to elucidate acute and long‐term effects within individual mice and remains a limitation of this study. Thus, longitudinal studies tracking individual animals are necessary in order to draw strong conclusions on age/time related effects. Additionally, while cervical dislocation as a secondary measure of euthanasia was applied consistently throughout the study, it may have contributed to disc height variability in data collected at the 60‐week timepoint, and future studies should consider in vivo microCT for disc height measurements to avoid ex vivo processing effects. Some histological sections (< 2 per group) may have been angled toward a sagittal versus coronal view; however, consistent medial sections were used with consistent grading criteria. While our data supports the growing body of literature indicating the negative impacts of HFD and the potential protective role of fat‐1 on IVD degeneration, further studies are warranted to elucidate the critical mechanisms driving obesity‐related IVD degeneration. Conclusion Obesity is a major risk factor for musculoskeletal diseases, including LBP and IVD degeneration. Our findings demonstrate that a high‐fat Western‐style diet enriched in omega‐6 fatty acids (n‐6 HFD) impairs metabolic function, alters systemic inflammatory profiles, and accelerates IVD degeneration. However, lowering the n‐6:n‐3 fatty acid ratio via the fat‐1 transgene effectively protected against obesity‐induced IVD degeneration in terms of preserving disc histopathological structure and reducing severity scores to comparable levels seen in lean controls. Importantly, this protection against structural degeneration occurred even in the presence of chronic weight gain, suggesting that the biochemical balance of fatty acids plays a critical role in IVD health, even in the context of mechanical overload due to increased body mass. Furthermore, we identified sexual dimorphisms in systemic inflammatory profiles, where fat‐1 modulation may promote anti‐inflammatory cytokine profiles in females and suppress pro‐inflammatory cytokines in males. Collectively, these results highlight the n‐6:n‐3 fatty acid ratio as a potential therapeutic target, suggesting that dietary interventions or gene therapies capable of correcting this ratio could serve as effective strategies for preventing or treating obesity‐related IVD degeneration. However, further mechanistic studies are warranted to fully establish the link between FA ratios, systemic or local inflammation, and their effect on the IVD. Author Contributions Farshid Guilak: conceptualization, funding acquisition, writing – review and editing, resources, supervision, project administration. Sarada Prasad: writing – review and editing, methodology, data curation, investigation. Emma Shen: investigation, writing – review and editing, methodology, formal analysis, data curation. Shirley N. Tang: conceptualization, investigation, writing – original draft, visualization, writing – review and editing, formal analysis, project administration, data curation, supervision, methodology. Arin K. Oestreich: project administration, supervision, resources, conceptualization, investigation, writing – review and editing, funding acquisition, methodology, validation, visualization, formal analysis, data curation. Collin Murray: investigation, writing – review and editing, methodology, data curation. Nikitha Ada: investigation, methodology, writing – review and editing, formal analysis, data curation. Mohammed Kuziez: investigation, writing – review and editing, data curation, formal analysis. Kristin L. Lenz: methodology, writing – review and editing, data curation, investigation, conceptualization. Funding This work was supported by the Shriner's Hospitals for Children and National Institutes of Health (NIH) grants: AR072999, AG46927, AR079045, AR080902, AR074992, AR073752, and DK056341 and T32 training grants: AR060719 and DK007120. Conflicts of Interest F.G. is an employee and shareholder in Cytex Therapeutics Inc. F.G. and A.K.O. are inventors on a patent (publication number: 20230059179), “Compositions and methods for regulating fatty acids.” The other authors declare no conflicts of interest. Supporting information Figure S1: 16 week disc height index. Figure S2: 60 week metabolic assessment. Figure S3: Female serum inflammation. Figure S4: Male serum inflammation. Figure S5: 60 week ex vivo disc height index. Table S1: Three‐way ANOVA results of female and male weekly growth curves. Table S2: Vertebral whole bone properties. Table S3: Vertebral cortical bone properties. Table S4: Vertebral trabecular bone properties.